Published online Apr 30, 2012.
https://doi.org/10.5534/kja.2012.30.1.1
5α-Reductase
Abstract
Androgen acts via the androgen receptor and can play a critical role in the development and growth of the prostate and the pathophysiology of prostatic diseases. Testosterone is the most abundant circulating androgen and is converted to dihydrotestosterone (DHT), a more potent androgen, by steroid 5α-reductase. There are two 5α-reductase isoenzymes, type 1 and type 2, in humans and animals. Type 2 5α-reductase predominates in the prostate. While deficiency of type 2 5α-reductase causes male pseudohermaphroditism, increased DHT has been implicated in benign prostatic hyperplasia and prostate cancer. The aim of this article is to highlight the significance of 5α-reductase in the development and growth of the prostate and pathogenesis of prostatic diseases.
Table 1
Comparison of the two human 5α-reductase isoenzymes
References
-
Veltri R, Rodriguez R. Molecular biology, endocrinology, and physiology of the prostate and seminal vesicles. In: Wein AJ, Kavoussi LR, Novick AC, Partin AW, Peters CA, editors. Campbell Walsh urology. 9th ed. Philadelphia: Saunders; 2006. pp. 2677-2726.
-
-
Roehrborn CG, McConnell JD. Benign prostatic hyperplasia: etiology, pathophysiology, epidemiology, and natural history. In: Wein AJ, Kavoussi LR, Novick AC, Partin AW, Peters CA, editors. Campbell Walsh urology. 9th ed. Philadelphia: Saunders; 2006. pp. 2727-2765.
-
-
Zhu YS, Sun GH. 5α-reductase isozymes in the prostate. J Med Sci 2005;25:1–12.
-
-
Iehlé C, Radvanyi F, Gil Diez de Medina S, Ouafik LH, Gérard H, Chopin D, et al. Differences in steroid 5alpha-reductase iso-enzymes expression between normal and pathological human prostate tissue. J Steroid Biochem Mol Biol 1999;68:189–195.
-
-
Habib FK, Ross M, Bayne CW, Bollina P, Grigor K, Chapman K. The loss of 5alpha-reductase type I and type II mRNA expression in metastatic prostate cancer to bone and lymph node metastasis. Clin Cancer Res 2003;9:1815–1819.
-
-
Park JS, Paick JS. Prostate disease and erectile dysfunction. In: Park JS, editor. Male sexual dysfunction. 2nd ed. Seoul: Koonja; 2008. pp. 581-670.
-
-
McConnell JD, Bruskewitz R, Walsh P, Andriole G, Lieber M, Holtgrewe HL, et al. Finasteride Long-Term Efficacy and Safety Study Group. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. N Engl J Med 1998;338:557–563.
-
-
McConnell JD, Roehrborn CG, Bautista OM, Andriole GL Jr, Dixon CM, Kusek JW, et al. Medical Therapy of Prostatic Symptoms (MTOPS) Research Group. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 2003;349:2387–2398.
-
-
Roehrborn CG, Siami P, Barkin J, Damião R, Major-Walker K, Nandy I, et al. CombAT study group. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study. Eur Urol 2010;57:123–131.
-
-
National Cancer Center. Goyang: National Cancer Center; [cited 2012 January]. Cancer registry system in Korea [Internet].Arailable from: http://www.ncc.re.kr.
-
-
Jaffe JM, Malkowicz SB, Walker AH, MacBride S, Peschel R, Tomaszewski J, et al. Association of SRD5A2 genotype and pathological characteristics of prostate tumors. Cancer Res 2000;60:1626–1630.
-
-
Walsh PC. Urological oncology: prostate cancer. J Urol 2004;171:506–517.
-
-
Andriole GL, Bostwick DG, Brawley OW, Gomella LG, Marberger M, Montorsi F, et al. REDUCE study group. Effect of dutasteride on the risk of prostate cancer. N Engl J Med 2002;362:1192–1202.
-
-
FDA core presentation: NDA020180/s034: Proscar (finasteride 5mg tablet). US Food and Drug Administration: December 1, 2010 Meeting of the Oncologic Drugs Advisory Committee. [cited 2012 March 27].Arailable from: http://www.fda.gov/downloads/Advisory-
Committees/CommitteesMeetingMaterials/Drugs/OncologicDrugsAdvisoryCommittee/UCM236786.pdf.
-
-
Uemura M, Tamura K, Chung S, Honma S, Okuyama A, Nakamura Y, et al. Novel 5 alpha-steroid reductase (SRD5A3, type-3) is overexpressed in hormone-refractory prostate cancer. Cancer Sci 2008;99:81–86.
-